# Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

> **NCT00399542** · PHASE3 · COMPLETED · sponsor: **Sucampo Pharma Americas, LLC** · enrollment: 581 (actual)

## Conditions studied

- Irritable Bowel Syndrome
- Constipation

## Interventions

- **DRUG:** Lubiprostone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00399542
- **Lead sponsor:** Sucampo Pharma Americas, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-05
- **Primary completion:** 2006-07
- **Final completion:** 2006-07
- **Target enrollment:** 581 (ACTUAL)
- **Last updated:** 2019-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00399542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00399542, "Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00399542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*